OBJECTIVE： To evaluate the efficacy and safety of Yupingfeng powder combined with second- generation antihistamines versus second-generation antihistamines for chronic urticaria （CU） systematically， and to provide evidence-based reference for clinical treatment for CU. METHODS： Retrieved from PubMed， Embase， The Cochrane Library， CJFD， VIP and CBM， RCT about therapeutic efficacy （total response rate， cure rate， recurrence rate） and safety （the incidence of ADR） of Yupingfeng combined with second-generation antihistamines （trial group） versus second-generation antihistamines （control group） in the treatment of CU were collected. The data extraction was performed for included clinical studies， and Meta-analysis was performed by using Rev Man 5.3 statistical software after quality evaluation with Cochrane Handbook 5.1.0 evaluation criteria. RESULTS： A total of 34 RCTs were enrolled， involved 3 405 patients in total. Results of Meta-analysis showed that the total response rate [OR＝4.02，95％CI（3.03，5.34），P＜0.001]， cure rate [OR＝2.25，95％CI（1.95，2.60），P＜0.001] and recurrence rate [OR＝0.33，95％CI（0.26，0.42），P＜0.001] of trial group were significantly better than those of control group， with statistical significance. There was no statistical significance in the incidence of ADR between 2 groups [OR＝0.98，95％CI（0.71， 1.37）， P＝0.92]. CONCLUSIONS： For CU therapy， Yupingfeng powder combined with second-generation antihistamines is better than second-generation antihistamines alone in improving total response rate and cure rate， reducing recurrence rate， both have similar safety.